CBUS
Cibus, Inc.
CBUS trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CBUS overall, supported by lower modeled downside and stronger fundamentals.
CBUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CBUS's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CBUS PE Valuation
CBUS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CBUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CBUS's revenue to grow, with its earnings and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CBUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.30 | +$2.03 |
| Q2 2026 | -$1.45 | +$9.07 |
| Q1 2026 | -$1.77 | +$9.28 |
| Q4 2025 | -$2.78 | +$8.05 |
| Q3 2025 | -$3.33 | +$26.78 |
| Q2 2025 | -$10.52 | +$13.55 |
| Q1 2025 | -$11.05 | +$14.93 |
| Q4 2024 | -$10.83 | +$19.48 |
CBUS is still losing money, but far less than before: $1.30 per share over the past year, against $68.00 at its worst in mid-2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CBUS on earnings quality, reporting a profit while its opponent remains loss making.
CBUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $800K | +30% |
| Q2 2026 | $994K | +6.5% |
| Q1 2026 | $1.7M | +63% |
| Q4 2025 | $1.1M | -13% |
| Q3 2025 | $615K | -63% |
| Q2 2025 | $933K | +11% |
| Q1 2025 | $1M | +90% |
| Q4 2024 | $1.2M | +9.9% |
CBUS's revenue is recovering but still below its 2020 peak: $800,000 last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1563% | +947 points |
| Q2 2026 | -1300% | +623 points |
| Q1 2026 | -721% | +3299 points |
| Q4 2025 | -2136% | -649 points |
| Q3 2025 | -2510% | +9514 points |
| Q2 2025 | -1923% | +640 points |
| Q1 2025 | -4020% | -635 points |
| Q4 2024 | -1487% | +22929 points |
CBUS's operating margin was −1563% last quarter, up 947 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CBUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CBUS on profitability, with a higher operating margin.
CBUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.3M | +$2.5M |
| Q2 2026 | -$9.4M | +$4.3M |
| Q1 2026 | -$11.6M | +$517K |
| Q4 2025 | -$13.5M | +$545K |
| Q3 2025 | -$11.8M | +$2M |
| Q2 2025 | -$13.7M | +$3.5M |
| Q1 2025 | -$12.1M | +$1.6M |
| Q4 2024 | -$14.1M | +$3.4M |
CBUS has burned cash in almost every quarter: −$44M over the past year, against −$52M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CBUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CBUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +137K shares |
| 1 year | +45% | +24M shares |
| 3 years | +7682% | +75.9M shares |
| 5 years | +10253% | +76.2M shares |
| Available history | +11620% | +76.2M shares |
CBUS has 77M diluted shares, up 45% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CBUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CBUS Net Leverage
CBUS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CBUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 4.7 | Oversold |
CBUS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CBUS PE vs Healthcare Sector
CBUS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CBUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.38 | 21% below |
| 20 week MA | $1.58 | 31% below |
| 50 week MA | $1.77 | 38% below |
| 100 week MA | $1.82 | 40% below |
| 200 week MA | $8.07 | 86% below |
CBUS is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CBUS on trend strength, trading above more of its moving averages.
CBUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $320.5 | $215.5 | -33% |
| 2021 | $215.5 | $111.5 | -48% |
| 2022 | $111.5 | $6.60 | -94% |
| 2023 | $6.60 | $19.6 | +198% |
| 2024 | $19.6 | $2.36 | -88% |
| 2025 | $2.36 | $1.70 | -28% |
| 2026 YTD | $1.70 | $1.09 | -36% |
CBUS's yearly returns have swung widely, from +198% in 2023 to −94% in 2022. It's down 36% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CBUS on returns for 2026, with the stronger performance.